Absci Corporation awarded a non-statutory stock option for 276,200 shares to a newly hired non-executive employee as an inducement to join the company. The grant was approved under Absci's 2023 Inducement Plan and complies with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $4.92 per share, matching the closing price on May 1, 2026, and vest over four years with a 10-year term. This move aims to attract talent to support Absci's AI-driven drug discovery efforts and ongoing development of innovative therapeutics like ABS-201 for hair regrowth and endometriosis.
Diana Burgon of Berkshire Hathaway HomeServices Bayside Realty was named to the 2025 Honor Society, recognizing the top 17% of sales professionals in the network. This award highlights her outstanding sales performance and dedication to clients. Sinc...
A new study found that adults with alcohol use disorder (AUD) who started treatment with GLP-1 receptor agonists like semaglutide and tirzepatide had significantly fewer alcohol-related hospitalizations compared to those on other diabetes or obesity ...
D.R. Horton reported Q3 earnings per share of $3.20, beating estimates, and revenues of $9.23 billion, slightly above expectations. Goldman Sachs raised its price target to $190 and maintained a "Buy" rating, signaling strong growth potential. Despit...
Interactive Brokers reported a strong Q2 with diluted EPS of $0.69 and net revenues of $1.90 billion, both exceeding analyst expectations. The company saw a 34% increase in client accounts and a 40% rise in client equity, driven by higher trading act...
United Rentals is set to report its Q2 2026 earnings on July 22, with analysts forecasting an 11.5% rise in earnings per share to $11.67 and a 7.3% increase in revenue to $4.23 billion. The growth is driven by strong rental demand and efficient equip...
